1. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer;Ching;Br. J. Clin. Pharmacol.,1991
2. CPMP (Committtee for Proprietary Medicinal Products) 1992 Working Party on the Efficacy of Medicinal Products, 1992. Note for Guidance: Investigation of Bioavailability and Bioequivalence.
3. FDA (US Food and Drug Administration), 1992. Guidance: Statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Informal communication under 21 CFR 10.90(b)(a).
4. Update on the statistical analysis of bioequivalence studies;Hauschke;Int. J. Clin. Pharmacol. Ther. Toxicol.,1992
5. Clinical pharmacology of omeprazole;Howden;Clin. Pharmacokinet.,1991